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Aims: The clinical diagnosis of metabolic syndrome does not find any parameters to evaluate the 
insulin sensitivity (IS) or β-cell function. The evaluation of these parameters would detect early 
risk of developing metabolic syndrome. The aim of this study is to determine the relationship 
between β-cell function and presence of metabolic syndrome in Mexican subjects.
Material and methods: This study is part of the Mexican Survey on the Prevention of 
  Diabetes (MexDiab Study) with headquarters in the city of Puebla, Mexico. The study comprised 
of 444 subjects of both genders, aged between 18 and 60 years and allocated into two study 
groups: (1) control group of individuals at metabolic balance without metabolic syndrome and 
(2) group composed of subjects with metabolic syndrome and diagnosed according to the criteria 
of the Third Report of the National Cholesterol Education Program Expert Panel on Defection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults. Anthropometric, biochemical, 
and clinical assessments were carried out.
Results: Average age of the subjects in the control group (n = 254) was 35.7 ± 11.5 years and 
42.0 ± 10.7 years for subjects in the metabolic syndrome group (n = 190). Subjects at metabolic 
balance without metabolic syndrome showed decreased IS, increased insulin resistance (IR), 
and altered β-cell function. Individuals with metabolic syndrome showed a high prevalence 
(P # 0.05) of family history of type 2 diabetes (T2D). This group also showed a significant 
  metabolic imbalance with glucose and insulin levels and lipid profile outside the ranges 
  considered safe to prevent the development of cardiovascular disease and T2D.
Conclusion: The main finding in this study was the detection of altered β-cell function, 
decreased IS, an increased IR in subjects at metabolic balance, and the progressive deterioration 
of β-cell function and IS in subjects with metabolic syndrome as the number of features of 
metabolic syndrome increases.
Keywords: insulin sensitivity, insulin resistance, family history of type 2 diabetes mellitus, 
metabolic syndrome, b-cell function
Introduction
In recent decades, Mexico has seen a rapid increase in the prevalence of chronic 
  degenerative diseases, particularly those of cardiovascular origin.1 Among these 
  diseases, the metabolic syndrome is highlighted. Metabolic syndrome, considered as a 
public health problem worldwide, has been defined as a set of metabolic abnormalities 
consisting of central obesity distribution, decreased levels of cholesterol linked to 
low-density lipoprotein cholesterol (LDL-C), high levels of triacylglycerides (TAG), 
increased blood pressure (BP), and hyperglycemia.2 Different criteria have been 
  proposed to clinically define this syndrome. The definition used to date is that proposed 
by the third report from the Adult Treatment Panel (ATP-III) of National Cholesterol Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Education Program (NCEP).3 This was proposed as a means 
of identifying individuals with increased coronary risk. Insu-
lin resistance (IR) has been proposed as a key player in the 
pathophysiology of the metabolic   syndrome and is considered 
as the root cause.4 However, there are studies that cast doubt 
on IR as an etiological factor responsible for the development 
of the metabolic syndrome and its complications.5
The interaction between defects in insulin sensitivity (IS) 
and β-cell function has been proposed as a mechanism for the 
development of the metabolic syndrome.5 It has been sug-
gested that β-cell function should be assessed relative to IS 
because it has been shown that subjects with type 2 diabetes 
(T2D), subjects at risk for T2D, and those subjects that are 
in a state of normoglycemia or hyperglycemia have poor 
β-cell function compared with controls with normal glucose 
tolerance.5 β-cell function has been estimated by various 
groups and shown to be clearly demonstrated that subjects 
at high risk of developing T2D (older individuals, women 
with a history of gestational diabetes or polycystic ovary 
syndrome, subjects with impaired glucose tolerance, and 
first-degree relatives of individuals with T2D) have impaired 
β-cell function. Furthermore, the progression from normal 
glucose tolerance to impaired glucose tolerance and T2D is 
associated with declining insulin secretion.5,6 In overweight 
Latino adolescents with family history of T2D (FH-T2D), 
impaired fasting glucose is associated with impaired β-cell 
function and therefore, may identify children likely to be at 
risk for progression to T2D.6
Decreased β-cell function and decreased IS are the 
two major risk factors for the development of T2D.7 The 
β-cell ability to compensate for a decrease in IS enables 
these   individuals to maintain normal glucose levels, 
notwithstanding β cell can no longer compensate.8 However, 
it is still unknown whether β-cell dysfunction, decreased IS, 
or combination of both defects are the primary abnormalities 
leading to T2D.9
However, the factors that may mediate the physiopathology 
of the metabolic syndrome are not entirely clear and, to the best 
of our knowledge, are not well described in Latin American 
subjects. The scarcity of information currently available 
regarding these mechanisms hinder our understanding of 
the primary events leading to the cascade of disorders that 
characterize this disease. To this end, we studied the relation-
ship between β-cell function and the presence of metabolic 
syndrome in subjects from Mexico and observed that the 
assessment of β-cell function in apparently healthy subjects 
may detect early stages of metabolic abnormalities.
Material and methods
Subjects and setting
Based on the Mexican Diabetes Prevention Study (MexDiab 
Study), which randomly enrolled individuals from urban and 
rural communities, the study population was selected   during 
the first stage. Inclusion criteria were Mexican subjects 
who resided in the city of Puebla, Mexico, of both genders 
(excluding women who were pregnant or breastfeeding) and 
aged between 18 and 60 years with or without a FH-T2D. 
The study population was selected from patients attending 
the Family Medical Unit No. 2 (UMF-2) of the Instituto 
Mexicano del Seguro Social (IMSS) in Puebla, Mexico. The 
protocol was approved by the Scientific Research and Ethics 
Committee of the IMSS.
clinical characterization
Participants who accepted to be included in the study were 
interviewed. A complete clinical history and physical 
examination were carried out, aimed at detecting the 
presence of a personal history of chronic or acute use of 
medications, alternative treatments, smoking, physical 
activity, obesity, cardiovascular disease (CVD), and FH-T2D. 
The latter concept was considered positive where there were 
first-degree relatives (mother, father, siblings, and children) 
with disease.
Smoking was considered positive if subjects were active 
smokers (one or more cigarettes daily) and alcoholism if 
subjects had an alcohol intake .10 beers of 325 mL each or 
300 mL of liquor (tequila, wine, whiskey, vodka, rum, and 
brandy) per month. Systolic blood pressure (SBP), diastolic 
blood pressure (DBP), and anthropometric measurements 
(weight, height, and waist circumference [WC]) were 
measured in a standardized manner.
BP was determined in a sitting position and after 
5 minutes of rest in accordance with the Mexican Official 
Standard (NOM-030-1999-SSA2) for prevention, treatment, 
and control of hypertension10 using a Baumanometer 
(Microlife AG, Heerbrugg, Switzerland) and stethoscope 
(3M LITTMAN Classic II, Neuss, Germany). The size, 
weight, and percentage body fat (%BF) were determined 
using an electronic digital scale (Tanita Body Composition 
Analyzer, Model TBF-215, Tokyo, Japan) with a capacity of 
200 g ± 100 kg. WC was established around the waist (using 
a fiberglass tape with SECA mark) in a position parallel to 
the floor at the midpoint between the lower edge of the last 
rib and the edge of the iliac crest, at the end of expiration. 
Body mass index (BMI) was calculated using the Quetelet Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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formula (weight in kilograms divided by height in meters 
squared).
Assay
Blood sample obtained by venipuncture was taken in 
all   participants after a 12-hour fast. We performed the 
determination of fasting glucose (Gluc0h) and fasting insulin 
(Ins0h), total cholesterol (TC), TAG, high-density lipoprotein 
cholesterol (HDL-C) and 2 hours after a 75-g glucose load 
for measuring levels of glucose (Glc2h) and insulin (Ins2h). 
All biochemical determinations were performed according 
to conventional laboratory protocols using the periodic end 
point method (enzymatic spectroscopic methods). The levels 
of plasma glucose and lipid profile were determined using 
the Synchron CX5 Analyzer System from Beckman Coulter 
(Fullerton, CA). The determination of insulin was performed 
by chemiluminescence in a sandwich enzyme immunoassay 
using anti-insulin mouse monoclonal antibodies with alkaline 
phosphatase. Luminometer used was the Beckman Coulter 
Access System.
IR was assessed by homeostatic model assessment 
(HOMA)-IR using the following formula: ([Glc0h 
(mmol/L)] × [Ins0h (µU/mL)])/22.517). IR was defined by a 
HOMA-IR . 2.5.11 IS was calculated from the index to check 
the quantitative insulin sensitivity (QUICKI) by the following 
formula: QUICKI = 1/(log Ins0h + log Glc0h mg/dL) and 
in accordance with the 0.357 cut-off point; lower numbers 
represent lower IS.12
Determination of β-cell function was performed using 
the homeostatic model HOMA-β, through the formula: 
HOMA-β = [20 × Ins0h]/[Gluc0h (mmol/dL) − 3.5].
According to the method of Modan et al13 hyperinsuline-
mia was defined as levels of Ins0h equal to or greater than 
the 75th percentile ($11.25 µU/mL).
LDL-C was determined using the formula of Friedewald14 
where very low-density lipoprotein (VLDL-C) = TAG/5 and 
LDL-C = TC − (VLDL-C + HDL-C).
To determine whether there was risk of developing CVD 
in the subjects, we calculated the rate of Castelli Cardiovas-
cular Index (CVI) with the formula: TC/HDL-C.
TAG/HDL-C index was calculated by dividing the con-
centration of TAG on HDL-C as determined by Boizel et al.15 
The cut-off point for cardiovascular risk was determined by 
TAG/HDL-C . 3.
Exclusion criteria were applied to subjects who did not 
sign informed consent, did not conclude the clinical history 
or blood sampling, or who had chronic proinflammatory 
diseases (arthritis, rhinitis, and trauma), endocrine diseases 
(hyperthyroidism and hypothyroidism), or any chronic 
  diseases (except hypertension and hyperlipidemia). Smoking 
and alcoholism were also considered as exclusion criteria, as 
well as subjects who had previous diagnosis of T2D.
Metabolic syndrome was defined according to the 
criteria of the NCEP ATP-III3 with WC values adjusted 
according to the Mexican population as suggested by Zimmet 
et al16 (NCEP ATP-III). Diagnosis of metabolic syndrome 
was established if 3 or more of the following risk factors 
were present: BP $ 130/85 mm Hg, Gluc0h $ 100 mg/dL, 
TAG  $150 mg/dL, HDL-C in men ,40  and 
women ,50 mg/dL, WC $ 90 in men and in women 
$80 cm.
Subjects were classified into two study groups: 
(1) metabolic syndrome group comprised of subjects 
with metabolic syndrome according to the criteria of 
NCEP ATP-IIIm and (2) control group comprised of 
subjects at metabolic balance without disabling physi-
cal illness and not using any medications. The con-
trol group met the   following   biochemical parameters: 
Gluc0h , 100 mg/dL, TAG # 150 mg/dL, HDL-C $ 40 
mg/dL, and BP , 130/,85 mm Hg. The control group was 
divided into subjects with low IS (QUICKI index ,0.357) 
and subjects with normal IS (QUICKI index $0.357). 
Metabolic syndrome subjects were divided into three groups 
according to the number of   features of   metabolic syndrome 
according to NCEP ATP-IIIm criteria.
Subsequently, all subjects were grouped according to the 
cut-off point of QUICKI index to determine the relationship 
between IS and the presence of metabolic syndrome.
Statistical analysis
The results were expressed as mean ± standard deviation. 
Differences between groups were considered significant at 
P # 0.05. To assess the normality, Kurtosis Normality of 
Residuals test was used. Continuous variables with normality 
and equal variances were analyzed using one-way analysis of 
variance. Differences between groups were analyzed by Tukey–
Kramer test or. If there were not normality but equal variances, 
Kruskal–Wallis test was used and differences between groups 
were determined by Kruskal–Wallis multiple comparisons of 
Z value. Nonparametric continuous variables were analyzed 
using Mann–Whitney U test and to establish their proportions, 
Fisher’s exact test was used. Spearman correlation test was 
used for variables. Data were analyzed with SPSS software 
(v. 12.0 for Windows; SPSS Inc., Chicago, IL).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Results
Of the subjects participating in the MexDiab Study and who 
were residents of the city of Puebla, Mexico, only 444 met 
the inclusion criteria to remain in the study. This population 
was assigned, according to previously established guidelines, 
to a control group (n = 254) and to the metabolic syndrome 
group (n = 190). Average age of the subjects in the control 
group was 35.7 ± 11.5 years and 42.0 ± 10.7 years for 
the metabolic syndrome group, with significant statistical 
difference between groups (P # 0.05).
Metabolic syndrome subjects compared with control 
group subjects had higher levels of SBP (115 ± 15 vs 
103 ± 12 mm Hg) and DBP (77 ± 10 vs 69 ± 8.0 mm Hg; 
P # 0.05). In addition, metabolic syndrome subjects had a 
higher prevalence of FH-T2D compared with control group 
(70.0% vs 52.4%; P # 0.05).
Table 1 describes the anthropometric and biochemical 
characteristics of study subjects with significant differ-
ences (P # 0.05) between groups according to the follow-
ing   variables: %BF, BMI, and WC. Moreover, taking into 
account data from the biochemical analysis, we found that 
metabolic syndrome group subjects showed a significant 
metabolic imbalance with levels of glucose, insulin, and 
lipid profile outside the ranges considered safe to prevent the 
development CVD and T2D. Table 1 also shows the variables 
of IR, IS, as well as β-cell function. One can see that the β-cell 
function is increased in subjects with metabolic syndrome 
and that matches with the lower IS present in these subjects. 
In addition, metabolic syndrome group presented a higher 
cardiovascular risk (assessed with CVI) compared with the 
control group (P # 0.05). This is supported by determining 
the TAG/HDL-C index, which was higher in the metabolic 
syndrome group compared with the control group (P # 0.05; 
Table 2); 161 subjects with metabolic syndrome had TAG/
HDL-C . 3.
Control group was divided according to the cut-off 
point of the QUICKI index ($0.357 and ,0.357; Table 3) 
in order to show the metabolic parameters to try to define 
the “premetabolic syndrome group”. We note that subjects 
at metabolic balance without metabolic syndrome but with 
IS low, showed levels of IR and β-cell function increased 
compared with the group of subjects at metabolic balance 
with adequate IS.
The prevalence of the features of the metabolic syn-
drome according to the criteria of NCEP ATP-IIIm was as 
follows: abdominal obesity (98.95%), hypertriglyceridemia 
(74.74%), low HDL-C (90.53%), hypertension (23.16%), 
and altered gluc0h (55.26%). Table 4 shows the character-
istics of the subjects in the metabolic syndrome group by 
number of features of metabolic syndrome according to the 
criteria of NCEP ATP-IIIm. It is demonstrated that with 
increased number of features of metabolic syndrome, there 
is increased abdominal obesity, BP, and glucose, insulin 
and TAG levels. It is also important to note that the degree 
of IR and IS, as well as β-cell function, is different between 
groups (P # 0.05).
Correlation analysis showed a strong relationship 
(P # 0.05) between the following variables that are 
Table  1  Anthropometric  and  biochemical  characteristics  of 
study groups
Study groups
Control 
n = 254
Metabolic syndrome 
n = 190
%BF 31.7 ± 8.3 36.7 ± 6.9*
BMi (kg/m2) 26.6 ± 4.6 30.9 ± 4.7**
Wc (M) (cm) 90.1 ± 14.8 103.7 ± 11.5**
Wc (W) (cm) 88.1 ± 10.8 98.7 ± 10.4**
gluc0h (mg/dL) 88.6 ± 6.4 105.4 ± 25.6*
gluc2h (mg/dL) 104.1 ± 20.6 143.3 ± 57.0*
ins0h (µU/mL) 6.7 ± 3.3 11.9 ± 5.8*
ins2h (µU/mL) 44.4 ± 29.4 86.1 ± 66.1*
hOMA-ir 1.5 ± 0.8 3.1 ± 1.9*
hOMA-β 98.9 ± 55.8 115.2 ± 62.3**
QUicKi 0.37 ± 0.03 0.33 ± 0.03*
Notes: results are expressed as mean ± standard deviation. 
*P # 0.05, Mann–Whitney U test; **P # 0.05, Kruskal–Wallis one-way analysis of 
variance.
Abbreviations: M, men; W, women; %BF, % body fat; BMi, body mass index;   
Wc, waist circumference; glc0h, fasting glucose; gluc2h, glucose 2 hours after 
a 75-g oral glucose load; ins0h, fasting insulin; ins2h, insulin 2 hours after a 75-g 
oral glucose load; hOMA-ir, homeostatic model assessment of insulin resistance; 
hOMA-β,  homeostatic  model  assessment  of  β-cell  function;  QUicKi,  index  to 
check the quantitative insulin sensitivity.
Table 2 Lipid profile of study groups
Study groups
Control 
n = 254
Metabolic syndrome 
n = 190
Tc (mg/dL) 186.4 ± 36.8 201.3 ± 42.2*
hDL-c (mg/dL) 47.4 ± 12.0 37.0 ± 8.5**
LDL-c (mg/dL) 117.9 ± 29.8 124.1 ± 36.8
VLDL-c (mg/dL) 21.1 ± 7.9 40.1 ± 17.5**
TAg (mg/dL) 105.3 ± 39.3 200.5 ± 87.5**
cVi 4.1 ± 1.0 5.6 ± 1.3**
TAg/hDL-c 2.4 ± 1.0 5.8 ± 3.0**
Notes: results are expressed as mean ± standard deviation. 
*P # 0.05, Kruskal–Wallis one-way analysis of variance; **P # 0.05, Mann–Whitney 
U test.
Abbreviations: Tc, total cholesterol; hDL-c, cholesterol combined with high-
density  lipoprotein;  LDL-c,  cholesterol  combined  with  low-density  lipoprotein; 
VLDL-c, cholesterol combined with very low-density lipoprotein; TAg, triacyl-
glycerides; cVi, castelli cardiovascular index.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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highly relevant to this study: BMI showed a correlation 
with HOMA-IR (r = 0.5389), QUICKI (r = −0.5392), 
and HOMA-β (r = 0.2555). The relationship between 
BMI and IS change among the groups: control group 
(r = −0.2728, P # 0.01), subjects with metabolic syndrome 
diagnosed with three criteria (r = −0.4066, P # 0.01), and 
subjects with metabolic syndrome diagnosed with five 
criteria (r = −0.5778, P # 0.01). Among these groups, 
there was no change in the relationship between BMI 
and HOMA-β. In subjects with metabolic syndrome, 
HOMA-β correlated significantly (P # 0.01) with TAG 
(r = 0.1682), glc0h (r = −0.4200), HDL-C (r = −0.2315), 
and WC (r = 0.2017). In addition, the diagnosis of meta-
bolic syndrome correlated with HOMA-β (r = 0.1473) 
and QUICKI (r = −0.5809), and between HOMA-β and 
QUICKI, there was a significant inverse relationship 
(r = −0.6234, P # 0.01).
Both study groups were divided according to the cut-off 
point of the QUICKI index ($0.357 and ,0.357; Table 5) 
in order to determine the relationship among IS, β-cell 
function, and presence of metabolic syndrome. We found 
that there was a significant difference between groups 
(P # 0.05) with regard to anthropometric and biochemical 
variables. It was further noted that the QUICKI $ 0357 
group showed the least number of subjects diagnosed with 
metabolic syndrome and a better β-cell function compared 
with the QUICKI , 0.357 group (15.6% vs 62.4%, respec-
tively, P # 0.05). FH-T2D was not different between these 
groups.
In this study, besides evaluating the IS using the QUICKI 
index, it was also assessed with HOMA-S% index. Similar 
results were found to apply to both indexes.
Discussion
Metabolic syndrome is a disease that is considered as a 
  growing public health problem worldwide and has been 
Table 3 comparison of metabolic variables in control group 
according to the cut-off point 0.357 of the QUicKi index
Control study group
QUICKI $ 0.357 
n = 175
QUICKI , 0.357 
n = 79
Age (years) 35.6 ± 11.3 34.6 ± 11.5
BMi (kg/m2) 25.4 ± 3.7 28.8 ± 5.2*
SBP (mm hg) 101.2 ± 11.9 103.2 ± 10.5
DBP (mm hg) 68.1 ± 8.3 70.4 ± 7.4**
gluc0h (mg/dL) 86.6 ± 6.5 91.3 ± 5.3*
gluc2h (mg/dL) 99.7 ± 19.5 108.1 ± 15.7**
ins0h (µU/mL) 4.7 ± 1.5 9.7 ± 2.8***
ins2h (µU/mL) 33.0 ± 20.8 60.4 ± 29.9***
hOMA-ir 1.0 ± 0.3 2.2 ± 0.6***
hOMA-β 77.0 ± 36.3 132.2 ± 69.5***
Tc (mg/dL) 182.9 ± 35.8 181.6 ± 34.1
hDL-c (mg/dL) 50.0 ± 12.9 42.7 ± 10.2*
TAg (mg/dL) 92.4 ± 29.7 102.8 ± 29.7*
TAg/hDL-c 2.0 ± 0.8 2.6 ± 1.0***
cVi 3.8 ± 0.9 4.4 ± 0.9*
Notes: results are expressed as mean ± standard deviation.
*P # 0.05, Kruskal–Wallis one-way analysis of variance; **P # 0.05, one-way analysis 
of variance; ***P # 0.05, Mann–Whitney U test.
Abbreviations: BMi, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; glc0h, fasting glucose; gluc2h, glucose 2 hours after a 75-g of 
glucose oral load; ins0h, fasting insulin; ins2h, insulin 2 hours after 75-g of oral 
glucose load; Tc, total cholesterol; hDL-c, cholesterol combined with high-density 
lipoprotein; TAg, triacylglycerides; hOMA-ir, homeostatic model assessment of 
insulin  resistance;  hOMA-β,  homeostatic  model  assessment  of  β-cell  function; 
QUicKi, index to check the quantitative insulin sensitivity; Fh-T2D, family history 
of type 2 diabetes mellitus; cVi, castelli cardiovascular index.
Table 4 characteristics of the subjects of the metabolic syndrome 
group according to number of features of metabolic syndrome 
according to the criteria of the nceP ATP-iiim
Study groups
3 
n = 86
4 
n = 81
5 
n = 23
Age (years)* 38.0 ± 10.0a 46.1 ± 9.9b 46.3 ± 10.9b
BMi (kg/m2)** 30.6 ± 4.6 30.7 ± 4.7 32.6 ± 5.0
Wc (cm)** 98.7 ± 11.2a 100.6 ± 11.0ab 103.5 ± 8.7b
SBP (mm hg)* 112.2 ± 12.0a 113.8 ± 15.9a 127.0 ± 13.3b
DBP (mm hg)* 75.5 ± 9.3a 76.5 ± 9.4a 84.3 ± 7.7b
gluc0h (mg/dL)** 100.7 ± 27.3a 109.1 ± 26.6b 109.5 ± 7.6c
gluc2h (mg/dL)** 129.9 ± 53.3a 150.1 ± 60.6b 169.7 ± 44.7c
ins0h (µiU/mL)** 11.5 ± 5.9 11.8 ± 5.6 13.5 ± 6.4
ins2h (µiU/mL)** 77.1 ± 57.1a 87.6 ± 67.2ab 114.0 ± 85.6b
hOMA-ir** 2.9 ± 2.0a 3.2 ± 1.7ab 3.7 ± 1.8b
hOMA-β** 129.2 ± 73.3a 103.5 ± 48.1b 104.1 ± 52.3ab
QUicKi* 0.34 ± 0.03a 0.33 ± 0.02ab 0.32 ± 0.02b
Tc (mg/dL)** 191.2 ± 37.5a 208.3 ± 44.5b 214.4 ± 43.6b
hDL-c (mg/dL)** 35.6 ± 9.8a 38.4 ± 7.3b 37.6 ± 6.6ab
LDL-c (mg/dL)** 120.5 ± 30.3 126.1 ± 42.9 130.9 ± 35.7
VLDL-c (mg/dL)** 35.1 ± 15.9a 43.7 ± 18.3b 45.8 ± 15.9b
TAg (mg/dL)** 175.7 ± 79.5a 218.7 ± 91.6b 229.2 ± 79.3b
TAg/hDL-c** 5.3 ± 2.8 6.1 ± 3.3 6.3 ± 2.3
cVi** 5.6 ± 1.4 5.6 ± 1.3 5.8 ± 1.1
Notes: results are expressed as mean ± standard deviation. 
*P # 0.05, one-way analysis of variance/Tukey–Kramer; **P # 0.05, Kruskal–Wallis 
one-way analysis of variance/Kruskal–Wallis multiple comparisons. Different letters 
(a, b, c) in a row indicate significant difference (P # 0.05) between groups.
Abbreviations: nceP ATP-iiim, third expert panel of the national cholesterol 
education  program-modified;  BMI,  body  mass  index;  WC,  waist  circumference; 
SBP,  systolic  blood  pressure;  DBP,  diastolic  blood  pressure;  glc0h,  fasting 
glucose; gluc2h, glucose 2 hours after a 75-g of glucose oral load; ins0h, fasting 
insulin; ins2h, insulin 2 hours after 75-g of oral glucose load; Tc, total cholesterol; 
hDL-c, cholesterol combined with high-density lipoprotein; LDL-c, cholesterol 
combined with low-density lipoprotein; VLDL-c, cholesterol combined with very 
low-density  lipoprotein;  TAg,  triacylglycerides;  hOMA-ir,  homeostatic  model 
assessment of insulin resistance; hOMA-β, homeostatic model assessment of β-cell 
function; QUicKi, index to check the quantitative insulin sensitivity; cVi, castelli 
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associated with a five fold increase in the prevalence of T2D 
and a greater than two fold increase in CVD prevalence.16,17 
We found that the assessment of β-cell function in relation 
to IS in subjects at metabolic balance without metabolic 
syndrome may detect early stages of metabolic abnor-
malities that characterize the metabolic syndrome and not 
only achieve early detection, but also enable strategies for 
prevention.
A surprise finding in this study was the detection of 
subjects at metabolic balance from the control group who 
presented glucose, TAG, HDL-C, and TC values within the 
appropriate range, but higher β-cell function, increased IR 
and decreased IS, similar to those seen in participants with 
metabolic syndrome. Therefore, these findings suggested 
that this may be the initial phase of the metabolic syndrome 
(premetabolic syndrome phase) and these metabolic abnor-
malities may serve as indicators and enable early detection 
of this disease and may be considered as a tool to prevent 
its development.
When analyzing the number of features of metabolic 
syndrome in the group of subjects with metabolic syndrome, 
it was observed that as age increased, the number of features 
of metabolic syndrome also increased. We also found that 
metabolic disturbances of the initial metabolic syndrome 
(subjects with only three diagnostic criteria of metabolic 
syndrome) are alterations in lipid profile, increase in β-cell 
function, increase of IR, decrease in IS, and adaptive hyperin-
sulinemia. Subsequently, as the number of diagnostic criteria 
of metabolic syndrome increased, we observed a dramatically 
and statistically significant increased in the levels of BP and 
glucose, we detected the gradual decrease of β-cell function 
and the IS.
As in the metabolic syndrome (observed in this study), in 
T2D the hyperglycemia is clearly the result of the interaction 
of defects in both IS and β-cell function. Thus with the 
realization that IS is a major determinant of the degree of 
β-cell function, it has become clear that defects in β-cell 
function are absolutely critical to the development of T2D. 
Furthermore, it has been demonstrated that defects in β-cell 
function are present long before the diagnostic criterion for 
T2D has been met.5
This is supported by the study of Festa et al18 in 
African-Americans, Hispanics, and white non-Hispanic 
study subjects. These authors found that in all three ethnic 
groups after a follow-up of 5.2 years, IS and β-cell function 
decreased in subjects on transition from tolerant to intoler-
ant to glucose and glucose intolerant to T2D. They also 
report that subjects with glucose tolerance who remained as 
tolerant despite the increase in body weight had the highest 
levels of IS and appropriate β-cell function in comparison 
with other subjects.
In addition, Arslanian et al19 found that children with 
FH-T2D compared with those who had no FH-T2D showed 
diminished IS and had a lower clearance of insulin as 
well as a disturbed relationship between the action of 
insulin and β-cell compensation. This is consistent with 
that reported in our study where subjects with metabolic 
syndrome had a higher prevalence of FH-T2D and lower 
IS and altered β-cell function in comparison with the 
control group.
According to the results reported in this study and 
others,20,21 one can see that the variation in the insulin 
released in response to changes in the IS are the result 
of changes in the secretory capacity of β cell, this is 
observed in the   different study groups. Thus, subjects with 
reduced IS have increased responses to glucose. On the 
other hand, insulin responses are small when IS is high. 
As expected, there was an inverse relationship between 
Table 5 comparison of metabolic variables in 444 study subjects 
according to the cut-off point 0.357 of the QUicKi index
Study groups
QUICKI $ 0.357 
n = 186
QUICKI , 0.357 
n = 258
Metabolic syndrome (%) 15.6 62.4*
Age (years) 39.2 ± 10.9 37.8 ± 12.1
BMi (kg/m2) 25.8 ± 3.8 30.3 ± 5.1**
Wc (cm) 86.7 ± 10.0 98.3 ± 12.1***
%BF 29.9 ± 8.4 36.6 ± 6.7**
Fh-T2D (%) 55.9 62.8
SBP (mm hg) 103.8 ± 12.9 110.8 ± 14.4***
DBP (mm hg) 69.4 ± 8.7 74.8 ± 9.5**
gluc0h (mg/dL) 88.1 ± 8.1 100.8 ± 22.0**
ins0h (µU/mL) 4.8 ± 1.4 11.9 ± 4.9**
hOMA-ir 1.1 ± 0.3 3.0 ± 1.6**
hOMA-β 76.5 ± 40.7 126.9 ± 61.3**
hDL-c (mg/dL) 47.6 ± 12.9 39.6 ± 9.6**
TAg (mg/dL) 109.7 ± 50.8 172.3 ± 86.5**
TAg/hDL-c 2.5 ± 1.5 4.8 ± 3.0**
cVi 4.2 ± 1.3 5.1 ± 1.3***
Notes: results are expressed as mean ± standard deviation.
*P # 0.05, Fisher’s exact test for two proportions; **P # 0.05, Mann–Whitney U 
test; ***P # 0.05, Kruskal–Wallis one-way analysis of variance.
Abbreviations: BMi, body mass index; Wc, waist circumference; %BF, % body fat; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; glc0h, fasting glucose; 
ins0h, fasting insulin; hDL-c, cholesterol combined with high-density lipoprotein; 
TAg,  triacylglycerides;  hOMA-ir,  homeostatic  model  assessment  of  insulin 
resistance; hOMA-β, homeostatic model assessment of β-cell function; QUicKi, 
index to check the quantitative insulin sensitivity; Fh-T2D, family history of type 2 
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β-cell function and the IS in subjects both with and without 
metabolic syndrome. This relationship was also reported 
by Dixon et al22 in nondiabetic subjects both before and 
after weight loss.
The importance of IS, as a modulator of β-cell function, 
is the detection of subjects with high risk of development 
of T2D, altered β-cell function is evident at a time when the 
fasting plasma glucose concentration is still well within the 
normal range.5
β-cell function is influenced throughout the life by a 
number of factors, some of which are potentially reversible. 
Abnormal β-cell function often has a genetic basis and 
  precedes the development of T2D. β-cell function deteriorates 
with age, but more rapidly in those with impaired glucose 
tolerance.22–26 Impaired insulin action and hyperglycemia 
adversely affect peripheral organ function and promote the 
development of other metabolic abnormalities characteristic 
of the metabolic syndrome.27
In this study, metabolic syndrome group subjects 
  compared with control group are in a state of compensatory 
hyperinsulinemia to the state of low IS, which is consistent 
with the increase in β-cell function present in these indi-
viduals. In addition, the group of subjects with decreased 
IS showed a higher prevalence of metabolic syndrome in 
comparison with the group with normal IS. This has also 
been reported in other studies,12 in which the population 
was of Czech origin and was initially divided into several 
groups depending on the metabolic alterations that had, like 
hyperlipidemia, glucose intolerance or both alterations, the 
QUICKI index ,0.357 distinctly identified patients with 
manifestations of metabolic syndrome.
Quantifying IS and β-cell function in humans is of great 
importance for epidemiological studies, clinical and basic 
science investigations, and eventual use in clinical practice. 
Direct and indirect methods of varying complexity are 
  currently employed for these purposes. Some methods rely 
on steady-state analysis of glucose and insulin, whereas 
others rely on dynamic testing. Thus, optimal choice and 
employment of a specific method depend on the nature of 
the studies being performed.
Simple surrogate indexes for IS and β-cell function are 
available that are derived from blood insulin and glucose 
concentrations under fasting conditions (steady state) or after 
an oral glucose load (dynamic). In particular, QUICKI index 
has been validated extensively against the reference standard 
glucose clamp method.28 QUICKI index is a simple, robust, 
accurate, reproducible method that appropriately predicts 
changes in IS.29 This index has been widely used30–32 and 
validated and has shown an excellent linear correlation with 
the glucose clamp index of IS and was significantly better 
than the minimal model index of IS at predicting IS, based 
on data from 116 glucose clamps obtained from nonobese, 
obese, T2D, and hypertensive subjects.33
On the other hand, the HOMA-β index is the result of 
a computer model. This model has been used to predict the 
homeostatic concentrations of glucose and insulin which 
arise from varying degrees β-cell deficiency and IR.34 
  Comparison of a patient’s fasting values with the model’s 
predictions allows a quantitative assessment of the contri-
butions of IR and deficient β-cell function to the fasting 
hyperglycemia (HOMA).34 The accuracy and precision of the 
estimate have been determined by comparison with indepen-
dent measures of IR and β-cell function using hyperglycemic 
and euglycemic clamps and an intravenous glucose tolerance 
test.34 This index has been widely used.35–37
Conclusion
In conclusion, this study detected altered β-cell function, 
decreased IS, an increased IR in subjects at metabolic 
balance without metabolic syndrome, and the progressive 
deterioration of β-cell function and IS in subjects with 
metabolic syndrome as the number of features of metabolic 
syndrome increases. This study suggests that the assessment 
of β-cell function in relation to IS in subjects at metabolic 
balance may detect early stages of metabolic abnormalities 
(premetabolic syndrome phase) that characterize metabolic 
syndrome and not only detect at an early stage, but also 
enable prevention strategies. The indices QUICKI and 
HOMA-β can be used in clinical practice to easily and 
accurately estimate the IS and β-cell function, respectively, 
in subjects at risk.
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